Today's Top Performers In Health Services

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 62 points (-0.4%) at 14,778 as of Wednesday, May 1, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 958 issues advancing vs. 1,966 declining with 114 unchanged.

The Health Services industry currently sits down 0.78 versus the S&P 500, which is down 0.42. Top gainers within the industry include PerkinElmer ( PKI), up 2.2%, and Medtronic ( MDT), up 0.6%. On the negative front, top decliners within the industry include Vanguard Health Systems ( VHS), down 7.18, Opko Health ( OPK), down 4.63, Mettler-Toledo International ( MTD), down 3.09, Mindray Medical International ( MR), down 1.85 and HCA Holdings ( HCA), down 1.23.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry higher today:

4. Parexel International Corporation ( PRXL) is one of the companies pushing the Health Services industry higher today. As of noon trading, Parexel International Corporation is up $2.23 (5.45) to $43.18 on heavy volume Thus far, 686,478 shares of Parexel International Corporation exchanged hands as compared to its average daily volume of 473,100 shares. The stock has ranged in price between $40.73-$43.25 after having opened the day at $41.46 as compared to the previous trading day's close of $40.95.

PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. Parexel International Corporation has a market cap of $2.4 billion and is part of the health care sector. The company has a P/E ratio of 31.8, above the S&P 500 P/E ratio of 17.7. Shares are up 37.4% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Parexel International Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Parexel International Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Parexel International Corporation Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, DaVita HealthCare Partners ( DVA) is up $0.75 (0.63) to $119.40 on average volume Thus far, 468,562 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 759,900 shares. The stock has ranged in price between $117.93-$120.57 after having opened the day at $118.65 as compared to the previous trading day's close of $118.65.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $12.6 billion and is part of the health care sector. The company has a P/E ratio of 21.8, above the S&P 500 P/E ratio of 17.7. Shares are up 7.3% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full DaVita HealthCare Partners Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Aetna ( AET) is up $0.64 (1.11) to $58.08 on average volume Thus far, 2.3 million shares of Aetna exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $57.45-$59.38 after having opened the day at $57.68 as compared to the previous trading day's close of $57.44.

Aetna Inc. operates as a diversified health care benefits company in the United States. The company operates in three segments: Health Care, Group Insurance, and Large Case Pensions. Aetna has a market cap of $18.3 billion and is part of the health care sector. The company has a P/E ratio of 11.7, below the S&P 500 P/E ratio of 17.7. Shares are up 24.0% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Aetna a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Aetna as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Aetna Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Humana ( HUM) is up $3.65 (4.93) to $77.76 on heavy volume Thus far, 3.6 million shares of Humana exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $76.09-$79.88 after having opened the day at $76.18 as compared to the previous trading day's close of $74.11.

Humana Inc., a health care company, offers insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in three segments: Retail, Employer Group, and Health and Well-Being Services. Humana has a market cap of $11.6 billion and is part of the health care sector. The company has a P/E ratio of 9.8, below the S&P 500 P/E ratio of 17.7. Shares are up 8.0% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Humana a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Humana Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

These Are the Biggest Winners and Losers in Activist Investing This Year

These Are the Biggest Winners and Losers in Activist Investing This Year

With Hurricane Harvey, We Are in the Crosshairs of Volatility: Market Recon

With Hurricane Harvey, We Are in the Crosshairs of Volatility: Market Recon

EY's Greene Sees More Med Tech, CRO Deals Ahead

EY's Greene Sees More Med Tech, CRO Deals Ahead

Stocks Lower as Crude Oil Slides on Supply Concerns

Stocks Lower as Crude Oil Slides on Supply Concerns

Steep Selloff Pulls Crude Into Bear Market, S&P 500 and Nasdaq Trade Lower